News >

New Era Begins of Molecular Monitoring and Targeted Therapy in AML

Caroline Seymour
Published: Thursday, May 02, 2019

Eric S. Winer, MD

Eric S. Winer, MD

In the current era of acute myeloid leukemia (AML), treatment plans can be tailored based on each patient’s molecular profile, which is far more than what cytogenetics allowed for, explained Eric S. Winer, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
The Patient and Provider Connection™: Effective Communication to Optimize the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic ConstipationOct 31, 20191.0
Publication Bottom Border
Border Publication